scispace - formally typeset
Search or ask a question
Author

Hiroshi Iwasaki

Other affiliations: Synchrotron Radiation Center
Bio: Hiroshi Iwasaki is an academic researcher from Ritsumeikan University. The author has contributed to research in topics: Diffraction & Phase transition. The author has an hindex of 9, co-authored 54 publications receiving 583 citations. Previous affiliations of Hiroshi Iwasaki include Synchrotron Radiation Center.


Papers
More filters
Patent
23 Feb 1990
TL;DR: A compound of the formula ##STR1## Z=--CH(OH), CH 2, CH 2 -COO.1/2Ca has HMG-CoA inhibiting effects, making them useful as inhibitors of cholesterol biosynthesis as discussed by the authors.
Abstract: A compound of the formula ##STR1## Z=--CH(OH)--CH 2 --CH(OH)--CH 2 --COO.1/2Ca have HMG--CoA inhibiting effects, making them useful as inhibitors of cholesterol biosynthesis. The compound may be prepared as a pharmaceutical for reducing hyperlipidemia, hyperlipoproteinemia or atherosclerosis.

219 citations

Journal ArticleDOI
TL;DR: It has been shown that these scaffolds can be used as a suitable replacement for the hexahydronaphthalene ring present in naturally occurring HMG-CoA reductase inhibitors.

78 citations

Journal ArticleDOI
TL;DR: First systematic chiral syntheses of two pairs of enantiomers with 3,5-dihydroxyheptenoic acid chain, associated with a potent synthetic statin NK-104 are reported.

44 citations

Journal ArticleDOI
TL;DR: In this article, the structure of the high-pressure high-temperature phase of bismuth BiIV was studied by means of synchrotron X-ray diffraction using powdered samples compressed in a cubic-type multi-anvil press MAX80.

26 citations

Patent
03 Aug 1988
TL;DR: A compound shown by formula I {R 1 -R 4 and R 6 are H, alkyl, 1-3C alkoxy, n-butoxy, CF 3, F, Cl, Br, phenyl, phenoxy, etc..
Abstract: NEW MATERIAL:A compound shown by formula I {R 1 -R 4 and R 6 are H, alkyl, 1-3C alkoxy, n-butoxy, CF 3 , F, Cl, Br, phenyl, phenoxy, etc. or R 1 and R 2 or R 3 and R 4 are bonded to form CH=CH-CH=CH; Y is CH 2 , CH 2 CH 2 , CH=CH, etc.; Z is group shown by formula II, formula III [Q is CO or C(OR 13 ) 2 , etc.; W is CO, C(OR 13 ) 2 , etc.; R 11 is H or alkyl; R 12 is H, hydrolyzable alkyl, NH 4 , Na, etc.; R 13 is alkyl], etc.; R 5 is H, alkyl, alkenyl, etc.}. EXAMPLE: (E)-3,5-Dihydroxy-7-[4'-(4"-fluorophenyl)-2'-(1"-methyle-thyl)-quinoline-3"- yl]-hept-6-enoic acid. USE: An antilipemic agent, antihyperlipoproteinemia agent and antiatherosclerosis agent. PREPARATION: An enal shown by formula IV is condensed with a double anion of acetoacetic ester to give a compound shown by formula V, which is reduced to give a corresponding compound shown by formula I (formula VI). COPYRIGHT: (C)1989,JPO&Japio

24 citations


Cited by
More filters
Journal ArticleDOI
TL;DR: Introduced to the Market in the Last Decade (2001−2011) Jiang Wang,† María Sańchez-Rosello,́‡,§ Jose ́ Luis Aceña, Carlos del Pozo,‡ and Hong Liu.
Abstract: Introduced to the Market in the Last Decade (2001−2011) Jiang Wang,† María Sańchez-Rosello,́‡,§ Jose ́ Luis Aceña, Carlos del Pozo,‡ Alexander E. Sorochinsky, Santos Fustero,*,‡,§ Vadim A. Soloshonok,* and Hong Liu*,† †Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China ‡Department of Organic Chemistry, Faculty of Pharmacy, University of Valencia, Av. Vicente Andreś Estelleś, 46100 Burjassot, Valencia, Spain Laboratorio de Molećulas Orgańicas, Centro de Investigacioń Príncipe Felipe, C/ Eduardo Primo Yuf́era 3, 46012 Valencia, Spain Department of Organic Chemistry I, Faculty of Chemistry, University of the Basque Country UPV/EHU, Paseo Manuel Lardizab́al 3, 20018 San Sebastian, Spain IKERBASQUE, Basque Foundation for Science, Alameda Urquijo, 36-5 Plaza Bizkaia, 48011 Bilbao, Spain Institute of Bioorganic Chemistry and Petrochemistry, National Academy of Sciences of Ukraine, Murmanska Street 1, 02660 Kyiv-94, Ukraine

3,368 citations

Patent
20 Jul 1990
TL;DR: In this article, a process for their preparation and pharmaceutically acceptable salts thereof is described, as well as a process to synthesize their precursors, including 3-carboxamide.
Abstract: [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-((1-­methylethyl)-3-phenyl-4-[(phenylamino)-carbonyl]-1H-­pyrrole-1-heptanoic acid or (2R-trans)-5-(4-fluorophenyl)-­2-(1-methylethyl-N,4-diphenyl-1-[2-(tetrahydro-4-hydroxy-6-­oxo-2H-pyran-2-yl)ethyl]-1H-pyrrole-3-carboxamide; a process for their preparation and pharmaceutically acceptable salts thereof.

538 citations

Patent
15 May 2003
TL;DR: In this article, an SGLT2 inhibiting compound is provided having the formula having the chemical structure, and a method is also provided for treating diabetes and related diseases employing an sGLT 2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.
Abstract: An SGLT2 inhibiting compound is provided having the formula[Chemical structure] A method is also provided for treating diabetes and related diseases employing an SGLT2 inhibiting amount of the above compound alone or in combination with another antidiabetic agent or other therapeutic agent.

327 citations

Journal ArticleDOI
TL;DR: 2-cyano-N-(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)acetamide was utilized as key intermediate for the synthesis of some new coumarin 2, pyridine 3,pyrrole 4, thiazole 7, and pyrazolo[5,1-c]triazine and aminopyrazole 9.

231 citations